News
UTSW introduces single-port robotic surgery for lung cancer
A team at UT Southwestern Medical Center is the first in North Texas to offer single-port robotic-assisted thoracoscopic lobectomy, a minimally invasive procedure for select patients with early-stage lung cancer.
Study reveals how RNA-modifying enzyme picks its targets
An RNA-modifying enzyme linked to cancer and neurological disorders selects its targets by recognizing specific RNA shapes and sequences, according to a study by UT Southwestern Medical Center researchers.
Should patients learn they have cancer from an online portal?
The widespread use of electronic patient portals to provide quick access to test results presents healthcare professionals with an important challenge: How should new cancer diagnoses be communicated?
FDA expands use of kidney cancer drug developed from UTSW research
Belzutifan, a first-in-class drug that arose from scientific discoveries at UT Southwestern Medical Center, has been approved by the Food and Drug Administration to treat some patients with earlier stage kidney cancers in combination with an immunotherapy drug.
Antibody may improve treatment response in lung cancer
An experimental antibody treatment that binds to a protein known as PCDH7 shrank tumors in preclinical models of non-small cell lung cancer (NSCLC), even those resistant to a targeted therapy, a study led by UT Southwestern Medical Center researchers showed.